Endogenous BioID elucidates TCF7L1 interactome modulation upon GSK-3 inhibition in mouse ESCs

Abstract

Modulation of Wnt target gene expression via the TCF/LEFs remains poorly understood. We employ proximity-based biotin labeling (BioID) to examine GSK-3 inhibitor effects on the TCF7L1 interactome in mouse ESCs. We generated ESC lines with biotin ligase BirA* fused to TCF7L1 by knocking it into the endogenous TCF7L1 locus or by inserting a doxinducible BirA*-TCF7L1 transgene into the Rosa26 locus. Induction yielded BirA*-TCF7L1 levels 3-fold higher than in the endogenous system, but substantial overlap in biotinylated proteins with high peptide counts were detected by each method. Known TCF7L1 interactors TLE3/4 and {beta}-catenin, and numerous proteins not previously associated with TCF7L1, were identified in both systems. Despite reduced BirA*-TCF7L1 levels, the number of hits identified with both BioID approaches increased after GSK-3 inhibition. We elucidate the network of TCF7L1 proximal proteins regulated by GSK-3 inhibition, validate the utility of endogenous BioID, and provide mechanistic insights into TCF7L1 target gene regulation.\n\nHighlightsO_LIBirA*-TCF7L1 at single-copy physiological levels generates robust BioID data\nC_LIO_LICHIR99021 reduces TCF7L1 levels but increases detectable TCF7L1-proximal proteins\nC_LIO_LIThe TCF7L1 interactome of largely epigenetic/transcription factors fluctuates with GSK-3 inhibition\nC_LIO_LIJMJD1C, SALL4 and BRG1/SMARCA4 are validated as TCF7L-interacting proteins\nC_LI